Bulletin
Investor Alert

Integra LifeSciences Holdings Corp.

NAS: IART

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

May 7, 2021, 4:02 p.m.

/zigman2/quotes/200866868/composite

$

74.22

Change

0.00 0.00%

Volume

Volume 3,505

Quotes are delayed by 20 min

/zigman2/quotes/200866868/composite

Previous close

$ 73.52

$ 74.22

Change

+0.70 +0.95%

Day low

Day high

$71.10

$74.48

Open

52 week low

52 week high

$42.12

$77.40

Open

Company Description

Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical, and Orthopedics and Tissue Technologies segments. The Codman Specialty Surgical segment refers to the company's neurosurgery busi...

Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical, and Orthopedics and Tissue Technologies segments. The Codman Specialty Surgical segment refers to the company's neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and precision tools and instruments business, which sells instrument patterns and surgical and lighting products to hospitals, surgery centers, and dental, podiatry, and veterinary offices. The Orthopedics and Tissue Technologies segment includes offerings such as skin and wound repair, bone and joint fixation implants in the upper and lower extremities, bone grafts, and nerve and tendon repair. The company was founded by Richard E. Caruso in 1989 and is headquartered in Princeton, NJ.

Valuation

P/E Current

46.80

P/E Ratio (with extraordinary items)

36.85

P/E Ratio (without extraordinary items)

41.32

Price to Sales Ratio

4.03

Price to Book Ratio

3.61

Price to Cash Flow Ratio

27.14

Enterprise Value to EBITDA

20.09

Enterprise Value to Sales

4.90

Total Debt to Enterprise Value

0.25

Efficiency

Revenue/Employee

370,775.00

Income Per Employee

36,187.00

Receivables Turnover

5.31

Total Asset Turnover

0.40

Liquidity

Current Ratio

3.09

Quick Ratio

2.31

Cash Ratio

1.17

Profitability

Gross Margin

58.67

Operating Margin

15.34

Pretax Margin

6.82

Net Margin

9.76

Return on Assets

3.87

Return on Equity

9.13

Return on Total Capital

6.96

Return on Invested Capital

4.59

Capital Structure

Total Debt to Total Equity

109.28

Total Debt to Total Capital

52.22

Total Debt to Total Assets

45.79

Long-Term Debt to Equity

98.78

Long-Term Debt to Total Capital

47.20

Officers and Executives

Name Age Officer Since Title
Dr. Stuart M. Essig 57 1997 Chairman
Mr. Peter J. Arduini 54 2010 President, Chief Operating Officer & Director
Mr. Glenn G. Coleman 51 2014 Chief Operating Officer & Vice President
Ms. Carrie Anderson 50 2019 Chief Financial Officer & Vice President
Dr. Kenneth E. Burhop 65 2014 Chief Scientific Officer & Vice President

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
04/16/2021 Glenn G. Coleman
Executive Vice President & COO
25,658   Disposition at $71.5 per share. 1,834,547
04/16/2021 Glenn G. Coleman
Executive Vice President & COO
25,658   Derivative/Non-derivative trans. at $19.41 per share. 498,021
04/14/2021 Glenn G. Coleman
Executive Vice President & COO
4,002   Disposition at $70.5 per share. 282,141
04/14/2021 Lisa Evoli
Executive Vice President &CHRO
1,785   Disposition at $70 per share. 124,950
04/14/2021 Lisa Evoli
Executive Vice President &CHRO
3,440   Disposition at $70 per share. 240,800
04/14/2021 Lisa Evoli
Executive Vice President &CHRO
1,081   Disposition at $70 per share. 75,670
04/14/2021 Lisa Evoli
Executive Vice President &CHRO
1,785   Derivative/Non-derivative trans. at $43.68 per share. 77,968
04/14/2021 Lisa Evoli
Executive Vice President &CHRO
3,440   Derivative/Non-derivative trans. at $56.23 per share. 193,431
04/09/2021 Glenn G. Coleman
Executive Vice President & COO
12,500   Disposition at $70 per share. 875,000
04/09/2021 Glenn G. Coleman
Executive Vice President & COO
12,500   Derivative/Non-derivative trans. at $19.41 per share. 242,625
03/29/2021 Glenn G. Coleman
Executive Vice President & COO
12,500   Disposition at $68.5 per share. 856,250
03/29/2021 Glenn G. Coleman
Executive Vice President & COO
3,000   Disposition at $68.5 per share. 205,500
03/29/2021 Glenn G. Coleman
Executive Vice President & COO
12,500   Derivative/Non-derivative trans. at $19.41 per share. 242,625
03/18/2021 Richard E. Caruso
730,000   Disposition at $68.14 per share. 49,742,200
03/18/2021 Stuart M. Essig
Director
214,553   Disposition at $68.14 per share. 14,619,641
03/13/2021 Peter J. Arduini
President & CEO; Director
368   Derivative/Non-derivative trans. at $68.1 per share. 25,060
03/13/2021 Peter J. Arduini
President & CEO; Director
272   Derivative/Non-derivative trans. at $68.1 per share. 18,523
03/13/2021 Peter J. Arduini
President & CEO; Director
258   Derivative/Non-derivative trans. at $68.1 per share. 17,569
03/13/2021 Carrie Anderson
Executive Vice President & CFO
522   Derivative/Non-derivative trans. at $68.1 per share. 35,548
03/13/2021 Glenn G. Coleman
Executive Vice President & COO
515   Derivative/Non-derivative trans. at $68.1 per share. 35,071
03/13/2021 Glenn G. Coleman
Executive Vice President & COO
523   Derivative/Non-derivative trans. at $68.1 per share. 35,616
03/13/2021 Glenn G. Coleman
Executive Vice President & COO
990   Derivative/Non-derivative trans. at $68.1 per share. 67,419
03/13/2021 Eric Stuart Schwartz
EVP, Chief Legal Officer & Sec
261   Derivative/Non-derivative trans. at $68.1 per share. 17,774
03/13/2021 Eric Stuart Schwartz
EVP, Chief Legal Officer & Sec
179   Derivative/Non-derivative trans. at $68.1 per share. 12,189
03/13/2021 Robert T. Davis
EVP & President, TT
210   Derivative/Non-derivative trans. at $68.1 per share. 14,301
03/13/2021 Robert T. Davis
EVP & President, TT
288   Derivative/Non-derivative trans. at $68.1 per share. 19,612
03/13/2021 Robert T. Davis
EVP & President, TT
208   Derivative/Non-derivative trans. at $68.1 per share. 14,164
03/13/2021 Michael McBreen
EVP & President, CSS
192   Derivative/Non-derivative trans. at $68.1 per share. 13,075
03/13/2021 Michael McBreen
EVP & President, CSS
113   Derivative/Non-derivative trans. at $68.1 per share. 7,695
03/13/2021 Michael McBreen
EVP & President, CSS
113   Derivative/Non-derivative trans. at $68.1 per share. 7,695
03/13/2021 Lisa Evoli
Executive Vice President &CHRO
111   Derivative/Non-derivative trans. at $68.1 per share. 7,559
03/13/2021 Lisa Evoli
Executive Vice President &CHRO
188   Derivative/Non-derivative trans. at $68.1 per share. 12,802
03/13/2021 Lisa Evoli
Executive Vice President &CHRO
112   Derivative/Non-derivative trans. at $68.1 per share. 7,627
03/13/2021 Jeffrey Alan Mosebrook
SVP, Fin & Princ Acct Officer
41   Derivative/Non-derivative trans. at $68.1 per share. 2,792
03/13/2021 Jeffrey Alan Mosebrook
SVP, Fin & Princ Acct Officer
102   Derivative/Non-derivative trans. at $68.1 per share. 6,946
03/13/2021 Jeffrey Alan Mosebrook
SVP, Fin & Princ Acct Officer
62   Derivative/Non-derivative trans. at $68.1 per share. 4,222
03/13/2021 Peter J. Arduini
President & CEO; Director
368   Derivative/Non-derivative trans. at $0 per share. 0
03/13/2021 Peter J. Arduini
President & CEO; Director
272   Derivative/Non-derivative trans. at $0 per share. 0
03/13/2021 Peter J. Arduini
President & CEO; Director
258   Derivative/Non-derivative trans. at $0 per share. 0
03/12/2021 Carrie Anderson
Executive Vice President & CFO
4,819   Award at $0 per share. 0
03/12/2021 Glenn G. Coleman
Executive Vice President & COO
6,807   Award at $0 per share. 0
03/12/2021 Eric Stuart Schwartz
EVP, Chief Legal Officer & Sec
2,411   Award at $0 per share. 0
03/12/2021 Robert T. Davis
EVP & President, TT
3,063   Award at $0 per share. 0
03/12/2021 Michael McBreen
EVP & President, CSS
2,893   Award at $0 per share. 0
03/12/2021 Lisa Evoli
Executive Vice President &CHRO
1,815   Award at $0 per share. 0
03/12/2021 Jeffrey Alan Mosebrook
SVP, Fin & Princ Acct Officer
1,327   Award at $0 per share. 0
03/02/2021 Eric Stuart Schwartz
EVP, Chief Legal Officer & Sec
4,212   Disposition at $69.1 per share. 291,049
03/02/2021 Michael McBreen
EVP & President, CSS
2,205   Disposition at $69 per share. 152,145
03/02/2021 Jeffrey Alan Mosebrook
SVP, Fin & Princ Acct Officer
1,058   Disposition at $68.7 per share. 72,684
03/02/2021 Michael McBreen
EVP & President, CSS
435   Derivative/Non-derivative trans. at $69.26 per share. 30,128
03/01/2021 Eric Ian Schwartz
EVP, Chief Legal Officer & Sec
1,669   Derivative/Non-derivative trans. at $69.43 per share. 115,878
02/25/2021 Eric Ian Schwartz
EVP, Chief Legal Officer & Sec
2,288   Disposition at $69.52 per share. 159,061
02/25/2021 Robert T. Davis
EVP & President, TT
24,941   Disposition at $69.48 per share. 1,732,900
/news/latest/company/us/iart

MarketWatch News on IART

  1. Integra LifeSciences price target raised to $70 from $60 at Truist Securities, stock rated buy

    10:51 a.m. Jan. 6, 2021

    - Tonya Garcia

  2. Integra LifeSciences downgraded to underweight from neutral at J.P. Morgan

    8:53 a.m. Oct. 8, 2020

    - Tomi Kilgore

  3. Smith & Nephew buying Integra LifeSciences unit

    8:18 a.m. Sept. 29, 2020

    - Steve Goldstein

  4. Integra LifeSciences started at buy with $55 stock price target at SunTrust RH

    6:55 a.m. April 3, 2020

    - Tomi Kilgore

  5. Integra LifeSciences started at buy with $56 stock price target at SunTrust RH

    8:25 a.m. Jan. 3, 2019

    - Tomi Kilgore

  6. Integra LifeSciences downgraded to neutral from overweight at J.P. Morgan

    7:22 a.m. Oct. 27, 2017

    - Tomi Kilgore

  7. Johnson & Johnson raises guidance as earnings beat

    7:53 a.m. Oct. 17, 2017

    - MarketWatch.com

  8. Integra LifeSciences to pay $1.05 bln to buy Johnson & Johnson's Codman Neurosurgery business

    8:12 a.m. Feb. 15, 2017

    - Tomi Kilgore

  9. Integra LifeSciences started at buy with $96 stock price target at UBS

    10:29 a.m. Dec. 12, 2016

    - Tomi Kilgore

  10. 11 medical-device stock picks for 2016

    2:24 p.m. Jan. 6, 2016

    - Philip van Doorn

  11. Integra on Solid Footing After Tornier Deal

    10:59 a.m. Sept. 8, 2015

    - Barron's Online

  12. Integra LifeSciences upgraded to outperform from market perform at Wells Fargo

    7:23 a.m. May 1, 2015

    - Tomi Kilgore

  13. Today’s Top 5 Stock Picks: Unloved, but Cash Rich

    8:38 a.m. April 3, 2015

    - Barron's Online

  14. Align Technology: Invisible Braces Equal Visible Gains

    12:41 p.m. Oct. 18, 2013

    - Barrons Blogs

  15. Health-Care Stocks That Made Healthy Gains

    3:01 p.m. May 21, 2013

    - Barron's Online

  16. Preview

    4:27 a.m. Oct. 20, 2012

    - Barron's Online

  17. Loading more headlines...
/news/nonmarketwatch/company/us/iart

Other News on IART

  1. ResMed (RMD) Q3 Earnings Surpass Estimates, Revenues Miss

    10:04 a.m. April 30, 2021

    - Zacks.com

  2. Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Guidance Up

    9:29 a.m. April 30, 2021

    - Zacks.com

  3. Syneos Health (SYNH) Q1 Earnings Top Estimates, Margins Up

    9:01 a.m. April 30, 2021

    - Zacks.com

  4. Oppenheimer Releases a Buy Rating on Integra Lifesciences (IART)

    9:55 p.m. April 28, 2021

    - SmarterAnalyst

  5. Notable earnings before Wednesday's open

    12:20 p.m. April 27, 2021

    - Seeking Alpha

  6. One Last Hurrah? The Stocks To Buy Now

    4:09 a.m. April 25, 2021

    - Seeking Alpha

  7. ResMed (RMD) to Report Q3 Earnings: What's in the Offing?

    8:41 a.m. April 23, 2021

    - Zacks.com

  8. Integra (IART) to Report Q1 Earnings: What's in the Offing?

    10:59 a.m. April 22, 2021

    - Zacks.com

  9. Orthopedic Space Gains Momentum in 2021: 5 Stocks in Focus

    8:34 a.m. April 22, 2021

    - Zacks.com

  10. Abbott (ABT) Q1 Earnings Miss, Diagnostic Test Sales Solid

    9:49 a.m. April 20, 2021

    - Zacks.com

  11. Integra (IART) Hits New 52-Week High: What's Driving It?

    8:09 a.m. April 20, 2021

    - Zacks.com

  12. Loading more headlines...

At a Glance

Integra LifeSciences Holdings Corp.

1100 Campus Road

Princeton, New Jersey 08540

Phone

1 6092750500

Industry

Medical Equipment/Supplies

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

Revenue

$1.37B

Net Income

$133.89M

Employees

3,700

/news/pressrelease/company/us/iart

Press Releases on IART

  1. Integra LifeSciences Holdings Corp. to Host Earnings Call

    6:45 a.m. April 28, 2021

    - ACCESSWIRE

  2. How to Develop Investment Plans for Integra Lifesciences Hldg #IART

    11:45 a.m. April 24, 2021

    - Stock Traders Daily

  3. Integra LifeSciences Appoints Shaundra Clay as Director

    4:15 p.m. April 1, 2021

    - GlobeNewswire

  4. When the Price of Integra Lifesciences Hldg $IART Talks, People Listen

    9:40 p.m. March 17, 2021

    - Stock Traders Daily

  5. Loading more headlines...
Link to MarketWatch's Slice.